🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation. In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine’s clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.
Myco | $Myco
Questions we answer:
– Is Mydecine Undervalued?
– What lessons from the cannabis boom can we apply to the shroom boom?
– Is natural psilocybin better than synthetic psilocybin?
– What is the entourage effect?
🔥 Invest in Psychedelic Startups with Us 🔥
go to https://theintegration.co and click on “invest in psychedelic startups”
The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics, psychedelic investing and psychedelic business.
⛓ All our links:
📝 My notes on psychedelic investing:
🎧 Listen on Spotify and other podcast platforms:
🐦 brom on twitter:
Tweets by therealbrom
🎇 Clips and other stuff on Instagram:
0:00 – intro
3:15 – Myco Overview
5:45 – who is Josh Bartch?
9:00 – Are Psychedelics just Cannabis 2.0?
11:30 – lessons learned in cannabis?
15:30 – Mydecine Functional Mushroom Research
21:30 – Mydecine’s Psilocybin for PTSD vs MAPS MDMA for PTSD
27:15 – Natural Psilocybin vs Synthetic Psilocybin
32:45 – Psilocybin for Smoking Cessation
48:00 – What does Big Pharma think of psychedelic medicine?
50:30 – Mydecine clinics?
53:30 – Is Mydecine Undervalued?
57:30 – Mydecine NASDAQ uplisting
1:03:00 – Post Interview Analysis
Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.